secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2026-05-21T11:34:37+00:00
Accession:  0001104659-26-064863
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis
--------------------------------------------------------------------------------

- FDA meeting held May 20, 2026 to review Phase 2 SHIMMER study results and registrational study design.
- Company believes it has a path forward for zervimesine (CT1812) to treat dementia with Lewy bodies patients with psychosis.
- Formal FDA minutes expected in June 2026.
- Cognition Therapeutics (NASDAQ: CGTX) is a clinical-stage company developing neurodegenerative disorder treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/0001104659-26-064863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/tm2615260d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-064863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer